# Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

> **NCT07041203** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Kristina Simonyan** · enrollment: 8 (estimated)

## Conditions studied

- Spasmodic Dysphonia
- Laryngeal Dystonia
- Voice Tremor

## Interventions

- **DRUG:** sodium oxybate

## Key facts

- **NCT ID:** NCT07041203
- **Lead sponsor:** Kristina Simonyan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07041203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07041203, "Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07041203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*